Manufacturer
Aurobindo Pharma Limited (Unit III),
Contents
Efavirenz 600 mg, lamivudine 300 mg, tenofovir disoproxil fumarate 300 mg
Indication
HIV-1 infection in adults & adolescents ≥12 yr & ≥40 kg.
Instruction
Should be taken on an empty stomach.
Drug interaction
Limited additive effect of abacavir, emtricitabine. Increased AUC of didanosine, tenofovir, amodiaquine, lorazepam. Additive toxicity w/ NNRTIs eg, nevirapine, etravirine. Decreased Ctrough & Cmin of amprenavir. Decreased AUC of indinavir, nelfinavir, atazanavir, darunavir, maraviroc, raltegravir, ketoconazole, itraconazole, posaconazole, clarithromycin, rifabutin, carbamazepine. diltiazem, atorvastatin, pravastatin, simvastatin, levonorgestrel, norelgestromin, methadone, buprenorphine. Increased AUC w/ ritonavir. Decreased exposure of lopinavir, quinine, lumefantrine, halofantrine, artemisin & its derivatives, Ca-channel blockers, etonogestrel, immunosuppressants, warfarin. Decreased AUC w/ rifampicin. Increased phenytoin clearance. Altered pharmacokinetics w/ voriconazole. Fosamprenavir, saquinavir, tipranavir.
Malaysia
